These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30049373)

  • 41. Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review.
    Zhao N; Zheng SY; Yang JJ; Zhang XC; Xie Z; Xie B; Su J; Chen ZH; Chen SL; Zhang N; Lou NN; Dong S; Wu YL
    Clin Lung Cancer; 2015 Mar; 16(2):e5-9. PubMed ID: 25496960
    [No Abstract]   [Full Text] [Related]  

  • 42. The next tier of EGFR resistance mutations in lung cancer.
    Tumbrink HL; Heimsoeth A; Sos ML
    Oncogene; 2021 Jan; 40(1):1-11. PubMed ID: 33060857
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Origin of the T790M mutation and its impact on the clinical outcomes of patients with lung adenocarcinoma receiving EGFR-TKIs.
    Dong Y; Zhou Z; Wang J; Ma L; Liu Z; Wang Y; Song J; Zhang S; Che N
    Pathol Res Pract; 2019 May; 215(5):946-951. PubMed ID: 30760406
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Different subtypes of EGFR exon19 mutation can affect prognosis of patients with non-small cell lung adenocarcinoma.
    Tian Y; Zhao J; Ren P; Wang B; Zhao C; Shi C; Wei B; Ma J; Guo Y
    PLoS One; 2018; 13(11):e0201682. PubMed ID: 30383772
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Jain A; Lim C; Gan EM; Ng DZ; Ng QS; Ang MK; Takano A; Chan KS; Tan WM; Kanesvaran R; Toh CK; Loo CM; Hsu AA; Devanand A; Lim CH; Koong HN; Koh T; Fong KW; Yap SP; Kim SW; Chowbay B; Oon L; Lim KH; Lim WT; Tan EH; Tan DS
    PLoS One; 2015; 10(5):e0123587. PubMed ID: 25955322
    [TBL] [Abstract][Full Text] [Related]  

  • 46. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
    Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
    Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sensitive detection of EGFR mutations in cerebrospinal fluid from lung adenocarcinoma patients with brain metastases.
    Yang H; Cai L; Zhang Y; Tan H; Deng Q; Zhao M; Xu X
    J Mol Diagn; 2014 Sep; 16(5):558-563. PubMed ID: 24994671
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prolonged response after the discontinuation of nivolumab after resistance to gefitinib.
    Sasatani Y; Okauchi S; Ohara G; Kagohashi K; Satoh H
    Clin Respir J; 2019 Oct; 13(10):657-658. PubMed ID: 31343829
    [No Abstract]   [Full Text] [Related]  

  • 49. Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma.
    Chang LC; Chen KY; Shih JY; Yu CJ; Hsieh MS
    J Thorac Oncol; 2017 Jul; 12(7):e94-e95. PubMed ID: 28629547
    [No Abstract]   [Full Text] [Related]  

  • 50. Afatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with Rare EGFR (in exon 18-T179X) Mutation - a Case Report.
    Čoupková H; Vyzula R
    Klin Onkol; 2018; 31(5):380-383. PubMed ID: 30541326
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lung carcinoma with diffuse cystic lesions misdiagnosed as pulmonary langerhans cell histocytosis: a case report.
    Gui X; Ding J; Li Y; Yu M; Chen T; Huang M; Xiao Y
    BMC Pulm Med; 2020 Feb; 20(1):30. PubMed ID: 32019517
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Peritoneal relapse from lung adenocarcinoma after a response to EGFR-TKI.
    Satoh H; Kagohashi K; Kurishima K
    Tuberk Toraks; 2013; 61(4):346-7. PubMed ID: 24506752
    [No Abstract]   [Full Text] [Related]  

  • 53. [Epidermal growth factor receptor (EGFR) mutation status before and after acquired resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma].
    Ye SB; Li R; Shi SS
    Zhonghua Bing Li Xue Za Zhi; 2017 Feb; 46(2):98-101. PubMed ID: 28173668
    [No Abstract]   [Full Text] [Related]  

  • 54. Durable Clinical Response of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in trans-C797S to Combination Therapy of First- and Third-Generation EGFR Tyrosine Kinase Inhibitors.
    Zhou Z; Zhao Y; Shen S; Gu L; Niu X; Xu Y; Zhang T; Xiang J; Mao X; Lu S
    J Thorac Oncol; 2019 Aug; 14(8):e157-e159. PubMed ID: 31075545
    [No Abstract]   [Full Text] [Related]  

  • 55. Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study.
    Kim IA; Lee JS; Kim HJ; Kim WS; Lee KY
    BMC Cancer; 2018 Jul; 18(1):768. PubMed ID: 30055587
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and EGFR-Mutated Lung Adenocarcinoma.
    Tambo Y; Sone T; Kasahara K
    J Thorac Oncol; 2017 Dec; 12(12):e199-e200. PubMed ID: 29169523
    [No Abstract]   [Full Text] [Related]  

  • 57. Different clinical effects upon separate inhibition of coexisting EGFR and PI3KCA mutations in a lung adenocarcinoma patient.
    Tiseo M; Bersanelli M; Perrone F; Tamborini E; Settanni G; Busico A; Rossi G; Ardizzoni A; Pelosi G
    Lung Cancer; 2015 Feb; 87(2):204-6. PubMed ID: 25555368
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (
    Han JY; Lee KH; Kim SW; Min YJ; Cho E; Lee Y; Lee SH; Kim HY; Lee GK; Nam BH; Han H; Jung J; Lee JS
    Cancer Res Treat; 2017 Jan; 49(1):10-19. PubMed ID: 27188206
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dioscin overcome TKI resistance in EGFR-mutated lung adenocarcinoma cells via down-regulation of tyrosine phosphatase SHP2 expression.
    Wang YC; Wu DW; Wu TC; Wang L; Chen CY; Lee H
    Int J Biol Sci; 2018; 14(1):47-56. PubMed ID: 29483824
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The genomic imprint of cancer therapies helps timing the formation of metastases.
    Németh E; Krzystanek M; Reiniger L; Ribli D; Pipek O; Sztupinszki Z; Glasz T; Csabai I; Moldvay J; Szallasi Z; Szüts D
    Int J Cancer; 2019 Aug; 145(3):694-704. PubMed ID: 30694556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.